Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.34
+0.35 (3.18%)
Mar 25, 2026, 4:00 PM EDT - Market closed
Keros Therapeutics Employees
Keros Therapeutics had 78 employees as of December 31, 2025. The number of employees decreased by 91 or -53.85% compared to the previous year.
Employees
78
Change
-91
Growth
-53.85%
Revenue / Employee
$3,128,987
Profits / Employee
$1,115,564
Market Cap
223.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 78 | -91 | -53.85% |
| Sep 30, 2025 | 82 | -78 | -48.75% |
| Jun 30, 2025 | 148 | -1 | -0.67% |
| Mar 31, 2025 | 163 | 22 | 15.60% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Sep 30, 2024 | 160 | 31 | 24.03% |
| Jun 30, 2024 | 149 | 28 | 23.14% |
| Mar 31, 2024 | 141 | 34 | 31.78% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Sep 30, 2023 | 129 | 25 | 24.04% |
| Jun 30, 2023 | 121 | 24 | 24.74% |
| Mar 31, 2023 | 107 | 32 | 42.67% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Sep 30, 2022 | 104 | 59 | 131.11% |
| Jun 30, 2022 | 97 | 53 | 120.45% |
| Mar 31, 2022 | 75 | 37 | 97.37% |
| Dec 31, 2021 | 60 | 25 | 71.43% |
| Sep 30, 2021 | 45 | 13 | 40.63% |
| Jun 30, 2021 | 44 | 16 | 57.14% |
| Mar 31, 2021 | 38 | 12 | 46.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Alector | 103 |
| Editas Medicine | 87 |
| Cybin | 50 |
| Camp4 Therapeutics | 48 |
| Sol-Gel Technologies | 34 |
KROS News
- 16 days ago - Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 16 days ago - Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - GlobeNewsWire
- 21 days ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 27 days ago - Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewsWire
- 5 weeks ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Final Results of Tender Offer - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Preliminary Results of Tender Offer - GlobeNewsWire
- 5 months ago - Keros Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire